Tonn J C, Wunderlich S, Kerkau S, Klein C E, Roosen K
Department of Neurosurgery, University of Wuerzburg, Germany.
Anticancer Res. 1998 Jul-Aug;18(4A):2599-605.
Glioma invasion is still a major obstacle for successful therapy. In the past we could demonstrate that glioma invasion is mediated by different adhesion molecules of the integrin family. Here we investigated whether a common pattern of integrin profiles might be involved, potentially providing a therapeutical avenue.
Multicellular spheroids were generated out of three human cell lines (GaMG, U373, U251) and from tumor biopsies of 9 human glioblastomas. After confrontation with rat brain aggregates, functional blocking antibodies against different integrin subunits (alpha 2, alpha 3, alpha v, alpha 1, alpha v beta 3, alpha v beta 5) or four different disintegrines (kistrin, echistatin, eristostatin, flavoridin) were added. Integrin patterns of the human cell lines/specimens were determined by FACScan or immunohistochemistry.
In cell lines, antibodies against alpha 2, alpha 3, alpha v and alpha v beta 5 effectively reduced invasion into rat brain aggregates. Little effect could be observed with the anti-beta 1- or with anti-alpha v beta 3- antibodies. In primary tumor specimens, however, a different invasion pattern in regard to its integrin dependency emerged with antibodies against the alpha 3-chain or the alpha v beta 3 integrin being the most effective. Invasion of primary tumor tissue into the brain aggregates was by far more aggressive compared to that of the cell lines. Accordingly, it was less influenced by integrin antibodies. The disintegrines affected migration of glioma cells on purified ECM substrates in a heterogeneous matter, but had no impact on tumor invasion into brain aggregates.
Although invasion of human gliomas is mediated by integrins, due to the heterogeneity of its dependency on different integrins this approach seems not to be appropriate to sufficiently alter glioma invasion in a therapeutical neuro-oncological setting.
胶质瘤侵袭仍是成功治疗的主要障碍。过去我们能够证明,胶质瘤侵袭是由整合素家族的不同黏附分子介导的。在此,我们研究了整合素谱的共同模式是否可能参与其中,这可能提供一种治疗途径。
从三种人类细胞系(GaMG、U373、U251)以及9例人类胶质母细胞瘤的肿瘤活检组织中生成多细胞球体。在与大鼠脑聚集体接触后,添加针对不同整合素亚基(α2、α3、αv、α1、αvβ3、αvβ5)的功能阻断抗体或四种不同的去整合素(抑肽素、echistatin、eristostatin、flavoridin)。通过流式细胞仪或免疫组织化学确定人类细胞系/标本的整合素模式。
在细胞系中,针对α2、α3、αv和αvβ5的抗体可有效减少对大鼠脑聚集体的侵袭。抗β1抗体或抗αvβ3抗体的作用不明显。然而,在原发性肿瘤标本中,出现了一种不同的整合素依赖性侵袭模式,其中针对α3链或αvβ3整合素的抗体最为有效。与细胞系相比,原发性肿瘤组织向脑聚集体的侵袭要激进得多。因此,它受整合素抗体的影响较小。去整合素以异质性方式影响胶质瘤细胞在纯化细胞外基质底物上的迁移,但对肿瘤向脑聚集体的侵袭没有影响。
尽管人类胶质瘤的侵袭是由整合素介导的,但由于其对不同整合素的依赖性存在异质性,在治疗性神经肿瘤学环境中,这种方法似乎不太适合充分改变胶质瘤的侵袭。